作者
Philipp Schuetz, Robert Birkhahn, Robert Sherwin, Alan E Jones, Adam Singer, Jeffrey A Kline, Michael S Runyon, Wesley H Self, D Mark Courtney, Richard M Nowak, David F Gaieski, Stefan Ebmeyer, Sascha Johannes, Jan C Wiemer, Andrej Schwabe, Nathan I Shapiro
发表日期
2017/5/1
期刊
Critical care medicine
卷号
45
期号
5
页码范围
781-789
出版商
LWW
简介
Objectives:
To prospectively validate that the inability to decrease procalcitonin levels by more than 80% between baseline and day 4 is associated with increased 28-day all-cause mortality in a large sepsis patient population recruited across the United States.
Design:
Blinded, prospective multicenter observational clinical trial following an Food and Drug Administration-approved protocol.
Setting:
Thirteen US-based emergency departments and ICUs.
Patients:
Consecutive patients meeting criteria for severe sepsis or septic shock who were admitted to the ICU from the emergency department, other wards, or directly from out of hospital were included.
Interventions:
Procalcitonin was measured daily over the first 5 days.
Measurements and Main Results:
The primary analysis of interest was the relationship between a procalcitonin decrease of more than 80% from baseline to day 4 and 28-day mortality using Cox …
学术搜索中的文章
P Schuetz, R Birkhahn, R Sherwin, AE Jones, A Singer… - Critical care medicine, 2017